Background
Methods
Statistical analysis
Results
Cohort demographics | AA | NAA | Total |
---|---|---|---|
N = 128 | N = 381 | N = 509 | |
Age (years) | |||
Median | 58 | 59 | 59 |
Sex | |||
Male | 63 (49) | 252 (66) | 315 (61) |
Admitting Unit | |||
Specialist medical | 73 (57) | 160 (42) | 233 (46) |
General medical | 23 (18) | 40 (11) | 63 (12) |
General surgical | 6 (5) | 31 (8) | 37 (7) |
Specialty surgical | 25 (2) | 147 (39) | 172 (34) |
Othera | 1 (1) | 3 (1) | 4 (1) |
Immunosuppressedb | |||
Yes | 33 (26) | 76 (20) | 109 (21) |
Total drug allergies | 128 (100) | 5 (1) | 133 (26) |
Total antimicrobials administered | 297 | 773 | 1070 |
Route of antimicrobial administration (n = 1070) | |||
Oral | 177(60) | 356 (46) | 533 (50) |
Intravenous | 102 (34) | 371 (48) | 473 (44) |
Otherc | 18 (6) | 46 (6) | 64 (6) |
Antimicrobial allergy descriptions
Reported Antimicrobial Allergy or ADR | Total |
---|---|
N = 202 (%) | |
Beta-lactams | 109 (54) |
Penicillina | 54 |
Amoxicillin/Ampicillin | 12 |
Amoxicillin-clavulanate | 5 |
Flucloxacillin | 3 |
Ticarcillin-clavulanate | 5 |
Piperacillin-tazobactam | 4 |
Cephalosporins (not specified) | 3 |
Cephalexin/Cephazolin | 14 |
Cefuroxime | 2 |
Ceftriaxone | 1 |
Ceftazadime | 3 |
Cefepime | 1 |
Meropenem | 2 |
Non-beta lactams | 93 (46) |
Vancomycin | 7 |
Clindamycin/lincamycin | 6 |
Trimethoprim-sulfamethoxazole | 21 |
Dapsone | 5 |
Clarithromycin | 2 |
Doxycycline | 2 |
Erythromycin | 11 |
Roxithromycin | 4 |
Metronidazole | 2 |
Tobramycin | 4 |
Aminoglycosides (NS) | 1 |
Norfloxacin | 1 |
Ciprofloxacin | 7 |
Moxifloxacin | 3 |
Antiretroviral therapy | 5 |
Azolesb | 6 |
Otherc | 6 |
Antimicrobial usage and appropriateness
AA group | |
---|---|
(n = 278) | |
1 | Ciprofloxacin 15 (5 %) |
2 | Cephazolin 13 (5 %) |
3 | Ceftazadime 12 (4 %) |
4 | Ceftriaxone 11 (4 %) |
5 | Meropenem 10 (4 %) |
NAA group | |
(n = 792) | |
1 | Cephazolin 69 (9 %) |
2 | Ceftriaxone 59 (7 %) |
3 | Piperacillin-tazobactam 47 (6 %) |
4 | Ciprofloxacin 40 (5 %) |
5 | Amoxicillin – clavulanate 33 (4 %) |